Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alex Carchidi calls the biotech sector highly risky and speculative, and says diversification is key for investors.

Biotech And Pharma Diversification Pays Off

Gilead Sciences (GILD) concluded the recent trading session at $79.48, signifying a +1.34% move from its prior day's close.

Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2023 financial results and guidance will be released on Tuesday, February 6, 2024 after the market closes. At 5:00 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's fourth quarter and full year 2023 financial results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilea.

Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024

Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.

Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal

Bristol-Myers

Johnson & Johnson

Legend Biotech

Novartis

The FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of their CAR T-cell immunotherapies after it identified adverse events.

FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels

Trodelvy did not perform well in an important clinical trial. Management is vowing to keep seeking other patient populations to treat with the drug.

Why Gilead Sciences Stock Got Mashed on Monday

Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) shares fell by their most since 2015 as the late-stage trial of its antibody-drug conjugate Trodelvy failed to show a significant improvement in the overall survival of patients with certain types of lung cancer. Shares of the biotech firm were down nearly 11% by midday Monday after the Phase 3 EVOKE-01 study did not meet the primary endpoint for patients with advanced or metastatic non-small cell lung cancer (NSCLC) who had previously received platinum-based chemotherapy or a checkpoint inhibitor.

Gilead shares plunge on lung cancer trial disappointment

Gilead will discuss the results with regulators and identify whether certain lung cancer patients may still benefit from the drug, known as Trodelvy.

Gilead stock falls after disappointing lung cancer study results

Gilead Sciences Inc (NASDAQ: GILD) says its drug conjugate Trodelvy disappointed in a late-stage cancer trial. Shares of the biotech firm opened about 10% down today.

Gilead says its Trodelvy disappointed in a late-stage cancer trial

Gilead said Monday its drug, Trodelvy, failed to pass muster in a study of patients with lung cancer, and GILD stock toppled.

Gilead Sciences Stock Crashes 9% After Cancer Drug Fails A Key Test

Shares of Gilead Sciences Inc. GILD, +1.03% tumbled 10.9% beating in premarket trading Monday, to pullback from an 11-month high, after the biotechnology company disappointing trial results of its lung cancer treatment. That selloff would put the stock in danger of the biggest one-day decline since it plunged 14.3% on Dec. 22, 2014.

Gilead's stock tumbles toward biggest selloff in more than 9 years after lung cancer treatment trial disappoints

Gilead Sciences on Monday said a late-stage trial of its antibody-drug conjugate Trodelvy failed to show that it significantly improved survival for previously treated patients with advanced non-small cell lung cancer (NSCLC).

Gilead says Trodelvy fails to meet primary goal in 2nd-line lung cancer trial

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). EVOKE-01 is evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) vs. docetaxel in patients with metastatic or advanced NSCLC that had progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy. A numerical improvement in O.

Gilead Provides Update on Phase 3 EVOKE-01 Study

Eli Lilly

Vertex Pharmaceuticals

For the past two years, biotech stocks have faced unfavorable conditions. These stocks have been on a downward spiral after reaching their pick at the beginning of 2021.

Bio-Revolution: 3 Biotech Stocks With Breakthrough Potential

AstraZeneca

Merck

By Feb. 1, the federal government will send an initial offer for each of the 10 drugs selected for the first round of negotiations under the program, which was established under the Inflation Reduction Act and touted by President Joe Biden as part of a broader effort to drive down healthcare costs. Yet several lawsuits challenging the program could also reach turning points in the coming months, raising the prospect that some elements of the program could be stalled before they get off the ground.

Medicare drug price negotiations hit critical phase

Amgen

Centene

Cencora Inc

Catalent

Medtronic

Moderna

Regeneron Pharmaceuticals

Viatris

The sector has seen one of the best starts to the year in decades, Goldman says.

10 Healthcare Stocks That Are Heating Up

Two sets of reliable stock market cycles have topped. Technically, the market does not appear as weak as expected.

Stocks This Week: Buy The Biotech Stocks: Amgen And Gilead

Every day for the next three weeks, we're going to highlight one of Schaeffer's top 12 picks for 2024.

Top Stock Picks for 2024: Gilead Sciences

Biotechnology company Gilead Sciences (NASDAQ: GILD ) wasn't a “Magnificent Seven” company or a darling of the financial markets in 2023. Yet, GILD stock deserves a long-overdue rally in 2024.

Gilead's Quiet Revolution: Is GILD the Next Big Stock to Soar?

Agilent Technologies

Core Laboratories Inc

Comcast

Compass Minerals

Campbell Soup

Corteva Inc

Disney

Estee Lauder

Emerson Electric

Etsy

Huntington Ingalls Industries

Harley-Davidson

Honeywell

International Flavors & Fragrances

Kenvue

McDonald's

Altria

NIKE

Otis Worldwide

PepsiCo

Pfizer

Polaris

Ross Stores

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).

U.S. Wide-Moat Stocks On Sale - The January 2024 Heat Map

Entergy

International Paper

This article introduces a dividend stock selection process called YARP (Yield At a Reasonable Price) that prioritizes risk management and total return. YARP aims to identify stocks with historically high dividend yields that are currently undervalued and have the potential for price appreciation. Within this article, I provide three stocks that meet the YARP criteria: Entergy, International Paper, and Gilead Sciences, highlighting their solid fundamentals, profitability, and dividend situations.

My Top 3 YARP Stocks Right Now (Yield At A Reasonable Price)

Up 2% five trading days into the new year, global health care stocks have already matched their return for all of 2023. It's very early, but the sector has outpaced all other 10 economic groups since the ball dropped in Times Square.

3 health care stocks off to strong starts in 2024

Gilead Sciences, Inc. (GILD) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

Sanofi

The Pharmaceutical segment offers human health pharmaceutical products in: Oncology, Hospital acute care Immunology Neuroscience Virology Cardiovascular and diabetes Vaccine products, such as preventive pediatric, adolescent, and adult vaccines The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.

7 Rock-Solid Healthcare Dividend Stocks to Buy in January

In the most recent trading session, Gilead Sciences (GILD) closed at $83.31, indicating a -1.38% shift from the previous trading day.

News for Gilead Sciences Stock (GILD)